TY - JOUR
T1 - Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria
T2 - A double-blind, randomized, placebo-controlled trial
AU - Monroe, Eugene
AU - Finn, Albert
AU - Patel, Piyush
AU - Guerrero, Robinson
AU - Ratner, Paul
AU - Bernstein, David
AU - Cohen, Robert M.
AU - Falliers, Constantine John
AU - Finn, Albert F.
AU - Hampel, Frank C.
AU - Heller, Alan M.
AU - Perin, Patrick V.
AU - Rowe, Michael S.
AU - Sim, Tommy Chua
AU - Miller, D. Lee
AU - Grubbe, Robert E.
AU - Berger, William
AU - Baker, James
AU - Raimer, Sharon A.
AU - Hamlin, Regina
AU - Stricker, William
AU - Van Bavel, Julius H.
AU - Bucko, Alicia D.
AU - Lynde, Charles
AU - Moote, Bill
AU - Sanchez, Mario
AU - Sussman, Gordon L.
AU - Ring, Johannes
AU - Fierlbeck, Gerhardt
AU - Ruzicka, Thomas
AU - Holst, Tormod
AU - Hornmark, Ann Marie
AU - Ceuppens, Jan
N1 - Funding Information:
Supported by a grant from Schering-Plough Research Institute.
PY - 2003/4/1
Y1 - 2003/4/1
N2 - Background: Chronic idiopathic urticaria (CIU) has a major impact on patient well-being. Antihistamines are the first-line treatment for CIU; however, some cause sedation. Objective: Our purpose was to study the efficacy and safety of desloratadine, 5 mg, a new H1-receptor antagonist, in patients with moderate to severe CIU. Methods: This study was a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of 6 weeks' duration. Results: Compared with placebo, desloratadine significantly improved the total CIU symptom score as well as pruritus, the number of hives, and the size of the largest hive. Overall therapeutic response and global CIU status improved significantly with desloratadine; interference with sleep was reduced and the performance of daily activities improved. Statistically and clinically significant improvements were seen within the first 24 hours of treatment and were sustained throughout the full duration of the study. The incidence of adverse events, including somnolence, was similar in the desloratadine and placebo groups. Conclusion: Desloratadine is a well-tolerated and effective treatment of CIU.
AB - Background: Chronic idiopathic urticaria (CIU) has a major impact on patient well-being. Antihistamines are the first-line treatment for CIU; however, some cause sedation. Objective: Our purpose was to study the efficacy and safety of desloratadine, 5 mg, a new H1-receptor antagonist, in patients with moderate to severe CIU. Methods: This study was a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of 6 weeks' duration. Results: Compared with placebo, desloratadine significantly improved the total CIU symptom score as well as pruritus, the number of hives, and the size of the largest hive. Overall therapeutic response and global CIU status improved significantly with desloratadine; interference with sleep was reduced and the performance of daily activities improved. Statistically and clinically significant improvements were seen within the first 24 hours of treatment and were sustained throughout the full duration of the study. The incidence of adverse events, including somnolence, was similar in the desloratadine and placebo groups. Conclusion: Desloratadine is a well-tolerated and effective treatment of CIU.
UR - http://www.scopus.com/inward/record.url?scp=0037380546&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037380546&partnerID=8YFLogxK
U2 - 10.1067/mjd.2003.143
DO - 10.1067/mjd.2003.143
M3 - Article
C2 - 12664016
AN - SCOPUS:0037380546
SN - 0190-9622
VL - 48
SP - 535
EP - 541
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 4
ER -